Physician profile
Aedra Andrade
NPI 1164435673
$726.26
in general payments reported to CMS, 2019-2025
16 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.09 · 2020: $51.97 · 2021: $16.82 · 2022: $53.31 · 2023: $123 · 2024: $69.84 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $161.20 | 2023-2025 | |
| Lilly USA, LLC | $86.86 | 2019-2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $68.09 | 2019-2025 | Spravato |
| Phathom Pharmaceuticals, INC. | $50.89 | 2024-2025 | Voquezna |
| Abbott Laboratories | $45.83 | 2025 | Freestyle Libre |
| Pfizer INC. | $43.19 | 2019-2023 | |
| Glaxosmithkline, LLC. | $38.18 | 2020-2024 | Rotarix, Pediarix, Bexsero |
| Abbvie INC. | $36.12 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $35.82 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $35.22 | 2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $31.59 | 2022-2025 | Breztri |
| Amarin Pharma, INC. | $31.52 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.86 | 2025 | Trintellix |
| Verona Pharma, INC. | $15.35 | 2025 | Ohtuvayre |
| Dexcom, INC. | $15.09 | 2025 | Dexcom G6 Transmitter |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aedra Andrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.